Skip to main content

Del Carmen Jeffrey's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Mar 30, 2023

Accession no.
0001161697-23-000201
Filed
Mar 30, 2023
Trade date
Mar 29, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $667.8K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Del Carmen JeffreyCIK 0001816477Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 29, 2023Common stock, par value $0.001 per shareMOption exerciseAcquired+20,983$2.24+$47,001.9228,524Direct
Mar 29, 2023Common stock, par value $0.001 per shareSSaleDisposed−20,983$16.70−$350,416.17,541Direct
Mar 29, 2023Common stock, par value $0.001 per shareMOption exerciseAcquired+19,017$4.21+$80,061.5726,558Direct
Mar 29, 2023Common stock, par value $0.001 per shareSSaleDisposed−19,017$16.69−$317,393.737,541Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 29, 2023Common StockMOption exerciseDisposed−20,983$0.00$0690,334Direct
Mar 29, 2023Common StockMOption exerciseDisposed−19,017$0.00$0671,317Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)